Detection And The Clinical Value Of CD98in The Sera Of NSCLC Patients

Background:Lung cancer is the most common cancer worldwide and causes more deaths per year than any other cancer. Early diagnosis of lung cancer has become a serious challenge to the scientific community. Currently, there are many clinical methods for detecting lung cancer, and each of them has certain limitation. Tumor markers attract many scholars’attentions due to the advantages on the early diagnosis of lung cancer and the potential application values for screening in the high risk group. With the development of the molecular biology and the human genome project, more and more specific tumor markers are identified. CD98is the heavy chain of a trans-membrane heterodimer on the cell surface and plays an important role in the development of cancer. It might be a potential novel tumor marker for diagnosis and prognosis of lung cancer. Objective:The purpose of the present study is to determine the role of CD98as a prognostic factor in a group of NSCLC patients and discuss the clinical significance of CD98in lung cancer. Methods: The CD98expression in72patients with NSCLC,27patients with nonmalignant lung diseases and27healthy persons were measured by a sandwich ELISA method. The sensitivity and specificity of CD98in NSCLC were calculated. The sensitivity of CD98in the diagnosis of NSCLC was also measured together with other biomarkers. Subsequently, a student t-test was used to examine the differences of CD98expression between NSCLC patients and healthy persons, and the correlation between CD98expression and the clinical pathological parameters was also analyzed. The Kaplan-Meier method was used to estimate survival as a function of time, and survival difference were analyzed by the log-rank test. Results:CD98expression in NSCLC patients was significantly increased (NSCLC, Mean6.94ng/ml±SD1.78; Healthy persons, Mean5.39ng/ml±SD1.65,P<0.01. In current study, the expression of CD98had correlation with clinical stages, the lymph node metastasis and the distant metastasis of tumor in NSCLC patients, P<0.05. Furthermore, the CD98expression was significantly correlated with the prognosis of NSCLC patients. The3-year survival rate of CD98-positive and-negative patients were0%and35.14%,respectively. The median survival times of CD98-positive and-negative patients were Meanllmonths±D3.86and Meanl6months±D4.05(P=0.013), respectively. The positive rate of CD98was23.6%with a specificity of96.3%in72NSCLC patients, and the positive detection rate of NSCLC was much improved by detecting CD98together with CEA、NSE、 SCC、CYFRA、ProGRP (50.94%) compared to the mentioned5-biomark detection alone (35.85%). Conclusion:Our results indicated that CD98expression was much higher in NSCLC patients than that in healthy persons. The CD98expression had close correlations with the clinical stages, the lymph node metastasis and the distant metastasis of tumor in NSCLC patients. CD98-positive NSCLC patients had a better prognosis than CD98-negative patients. CD98as a potential tumor marker might be used for clinical diagnosis and prognosis in NSCLC patients.